A Phase 1/2a Multicenter, Open-Label Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer

Trial Profile

A Phase 1/2a Multicenter, Open-Label Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs LYC 55716 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms ARGON
  • Sponsors Lycera
  • Most Recent Events

    • 12 Sep 2017 Results for the first three cohorts of the Phase 1 portion of the study will be available at the time of presentation as per trial design presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress
    • 11 Sep 2017 According to a Lycera Corp. media release, the trial is expected to be fully enrolled by mid-2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top